Table 1.
Baseline characteristics
| Controls | Primary/Secondary syphilis | Latent Syphilis | |||
|---|---|---|---|---|---|
| (n = 30) | HIV+ (n = 44)# | HIV-(n = 10)# | HIV+ vs. HIV-, P$ | HIV+(n = 35)# | |
| Men | 30 (100%) | 44 (100%) | 9 (90%)* | 0.0359 | 35 (100%) |
| Age (years) | 37 (32–45) | 39.5 (30.5–50.0) | 34 (30–43) | 0.4689 | 40 (35–46) |
| MSM | 24 (80%) | 44 (100%) | 9 (90%) | 0.0359 | 34 (94.7.1%) |
| CD4 T cell count (cells per μL) | 577 (392–684) | 649 (452–838) | 800 (800–800) | 0.4537 | 590 (433–691) |
| HIV Viral Load (copies per mL) | 34 (10–814) | 10 (10–53)* | NA | NA | 10 (10–25)** |
| On Antiretroviral Therapy | 24 (80%) | 39 (88.6%) | NA | NA | 31 (88.6%) |
| RPR titre | 0 (0–0) | 1/64 (1/32–1/128) | 1/64 (1/16–1/128) | 0.5556 | 1/64 (1/16–1/128) |
| Treatment | 1.0 | ||||
| Benzathine-penicillin G | NA | 44 (100%) | 10 (100%) | 33 (94.3%) | |
| Doxycycline | NA | 0 | 0 | 2 (5.7%) | |
| Previous treated syphilis | NA | 27 (61.3%) | 3 (30%) | 0.0743 | 24 (68.6%) |
| Other STIs presenta | 0 (30) | 1 (2.3%) | 0 (0%) | 0.63 | 2 (5.7%) |
| No. of sex partners prior 12 months | 1.5 (1–6) | 8.5 (2–26)** | 6.5 (2–8)* | 0.5174 | 7 (1–12)* |
Data are n (%), median (IQR), unless otherwise stated. NA - Not Applicable
*P < 0.05, ** P < 0.005
# P-value is for comparison with controls at baseline (Mann-Whitney U-test, excluding ‘Men’, ‘MSM’, ‘On Antiretroviral Therapy’ and ‘Other STIs’ where Fisher’s exact test used)
$ P-value is for comparison between HIV-infected and uninfected groups (Mann-Whitney U-test, except ‘Men’, ‘MSM’, ‘Treatment’, ‘Previous treated syphilis’ and ‘Other STIs’ where Fisher’s exact test used)
aPresence of N. gonorrhoeae or C. trachomatis in urethra, rectum or oropharynx
MSM: men who have sex with men